CD274 and lung carcinoma: Therefore, we assessed a series of lung cancer cell lines with wide range of known sensitivity to erlotinib (Table 1) for the impact of EGFR inhibitors on MHC-I, MHC-II, and PD-L1 expression in the presence or absence of inflammatory cytokine, IFNγ (Figs 2, 3 and 4).